A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test

Roche

Status: Enrolling

Conditions: Solid Tumours

Study type: Observational

Funder types: Industry

Identifiers

NCT04529122

MX39897

Details and patient eligibility

About

WAYFIND-R is a registry that aims to capture high-quality real-world data linking next-generation sequencing, treatments and outcomes from cancer patients diagnosed with a solid tumour. The WAYFIND-R has three main overarching objectives: 1. To provide a platform to support the design and conduct of clinical and epidemiological research; 2. To develop an evidence-generation platform to better understand health outcomes and cancer care processes; and 3. To characterize the treatments and clinical course of solid tumor cancers in patients who have undergone NGS testing.

Enrollment: 15,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participant is an adult (according to the age of majority as defined by local regulations)
• Participant is currently diagnosed with any type of solid tumour cancer, at any stage of the disease, at the enrollment date (informed consent date)
• Participant has undergone NGS testing, no longer than 3 months prior to the enrollment date, irrespective of the availability of test results
• Informed consent has been obtained from the participant or legally authorized representative, as per local regulations

Exclusion criteria

-Participant has a prior or current diagnosis of haematological malignancy